Molecular Pathology of
Cervical Cancer
Cervical Cancer
|
Molecular Pathology of Cervical Cancer |
| Home | • | About | • | Our Team | • | Expert Opinion | • | CuraBase Workspace | • | Contact |
|
| Region | Incidence Overall | Incidence Males | Incidence Females | Deaths Overall | Deaths Males | Deaths Females |
|---|---|---|---|---|---|---|
| USA | 12200 | 12200 | 4210 | 4210 |
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EGFR (ErbB-1 receptor) | Receptor Tyrosine Kinase Signaling |
primary cervical cancers | 64% | overexpression by immunohistochemistry | ||||||||
| p53 | p53 Tumor Suppressor Pathway |
7% | ||||||||||
| Pi3-kinase | PI3-Kinase Signaling |
invasive cervical carcinomas | 8% | the mutation rate was significantly higher in patients older than 60 years | ||||||||
| PTEN | PI3-Kinase Signaling |
15% | ||||||||||
| PTEN | PI3-Kinase Signaling |
high-grade cervical intraepithelial neoplasia (CIN-H) | 40% | |||||||||
| PTEN | PI3-Kinase Signaling |
squamous cell carcinoma (SCC) | 58% |
| See Clinical Trials in in the TTC Database |